In recent years, a number of organizations have developed value frameworks to assess new treatments. These organizations include the Institute for Clinical and Economic Review (ICER), Memorial Sloan Kettering Memorial Cancer Center (Drug Abacus), American Society for Clinical Oncologists (ASCO), National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (Magnitude of Clinical Benefit Scale). What are the best practices to conduct these value analyses?
The National Pharmaceutical Council has put together 28 recommendations for how best to conduct these value assessments. The recommendations are divided into six categories: assessment process, methodology, benefits, costs, evidence, and dissemination and utilization.
The infographic below summarizes their recommendations.
Source: National Pharmaceutical Council